Sign In
Buy FDMT
$9.53
+0.260 (+2.80%)
At Close: Jun 03, 2026
4D Molecular Therapeutics: Some Failures, A Few Key Successes
12:19pm, Monday, 25'th Sep 2023
4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions in patients. The company has five product candida
4DMT to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 07'th Sep 2023
EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for gen
4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal Performance
11:19am, Monday, 10'th Jul 2023
4D Molecular Therapeutics demonstrates a robust economic position and promising line-up of gene therapies, with a commitment to innovation and strategic financial management. The company's financials
4D Molecular Therapeutics: A Complicated Story
10:15am, Friday, 07'th Jul 2023
Shares of "directed evolution" genetic medicine concern 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. The company's approach to AAV de
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Thursday, 01'st Jun 2023
EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic me
Andreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeutics
05:57pm, Friday, 12'th May 2023
Viking Global Investors LP, the firm managed by Andreas Halvorsen (Trades, Portfolio), disclosed in a regulatory filing that it boosted its holding in 4D Molecular Therapeutics ( FDMT , Financial) in
4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?
07:39am, Monday, 08'th May 2023
4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into fu
4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?
06:08am, Friday, 14'th Apr 2023
4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth
4D Molecular Therapeutics: Promising Preliminary Safety And Efficacy For 4D-310
01:38am, Saturday, 25'th Mar 2023
With its strong focus on product design and development excellence, as evidenced by its sustained success in IND clearance, 4D Molecular Therapeutics is a promising biotech company with significant gr
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates
07:05pm, Wednesday, 15'th Mar 2023
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for
EMERYVILLE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT'), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targe
4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile
08:55am, Tuesday, 03'rd Jan 2023
FDMT is an undercovered gene therapy developer. It claims certain competitive differences for its vector delivery platform.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
10:55pm, Tuesday, 13'th Dec 2022
Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
05:39am, Sunday, 20'th Nov 2022
Recent analyst upgrades suggest these stocks can triple your money or better.
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why
12:02pm, Thursday, 17'th Nov 2022
4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.
